Valuation: Haleon plc

Market Cap 29.8B 39.82B 35.72B 32.64B 56.14B 3,743B 57.91B 393B 157B 1,997B 149B 146B 6,305B P/E 2026 *
17.7x
P/E 2027 * 15.8x
Enterprise Value 36.93B 49.35B 44.26B 40.45B 69.57B 4,639B 71.77B 488B 194B 2,475B 185B 181B 7,814B EV / Sales 2026 *
3.27x
EV / Sales 2027 * 3.12x
Free-Float
98.31%
Yield 2026 *
2.37%
Yield 2027 * 2.6%
1 day-0.53%
1 week+6.11%
Current month+6.11%
1 month-1.02%
3 months-8.26%
6 months+1.13%
Current year-9.58%
1 week 316
Extreme 316
344.1
1 month 310.5
Extreme 310.5
433.6
Current year 310.5
Extreme 310.5
433.6
1 year 310.5
Extreme 310.5
433.6
3 years 274.4
Extreme 274.4
433.6
5 years 241.17
Extreme 241.1735
433.6
10 years 241.17
Extreme 241.1735
433.6
Manager TitleAgeSince
Chief Executive Officer 59 22/07/2021
Director of Finance/CFO 58 01/11/2024
Chief Tech/Sci/R&D Officer 63 01/08/2025
Director TitleAgeSince
Director/Board Member 59 23/05/2022
Chairman 71 01/01/2026
Director/Board Member 59 18/07/2022
Date Insider Type Main position Quantity % Market Cap. Importance
22/09/26 Buy 2,139 0.0000%
22/09/26 Buy 12,209 0.0001%
22/09/26 Buy

Chief Financial Officer

2,317 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%+6.11%-6.17%+3.80% 39.82B
-0.79%-4.48%+46.48%+125.69% 1,206B
+1.43%+1.11%+48.05%+83.05% 665B
+1.07%-1.21%+32.92%+104.92% 515B
-0.36%-3.25%+45.42%+65.10% 381B
-0.14%-1.87%+70.06%+41.09% 362B
-0.78%-0.52%+30.47%+58.09% 307B
-0.80%-0.21%+7.98%+36.17% 289B
+0.03%-1.20%+43.79%+69.83% 249B
-0.41%-2.22%+40.43%+107.03% 207B
Average -0.13%-0.77%+35.94%+69.48% 421.96B
Weighted average by Cap. -0.05%-1.88%+42.25%+87.32%

Financials

2026 *2027 *
Net sales 11.29B 15.09B 13.53B 12.37B 21.27B 1,418B 21.94B 149B 59.44B 757B 56.63B 55.42B 2,389B 11.67B 15.59B 13.99B 12.78B 21.98B 1,466B 22.68B 154B 61.43B 782B 58.53B 57.27B 2,469B
Net income 1.67B 2.23B 2B 1.83B 3.14B 210B 3.24B 22.04B 8.79B 112B 8.37B 8.19B 353B 1.83B 2.44B 2.19B 2B 3.44B 230B 3.55B 24.13B 9.62B 122B 9.17B 8.97B 387B
Net Debt 7.13B 9.53B 8.55B 7.81B 13.43B 896B 13.86B 94.15B 37.54B 478B 35.77B 35B 1,509B 6.64B 8.88B 7.96B 7.28B 12.52B 835B 12.91B 87.72B 34.98B 445B 33.32B 32.61B 1,406B
Projected Income Statement - Annual - Haleon plc
Logo Haleon plc
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (31.4%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - pain relief medicines (23.2%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - respiratory medicines (17%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (15.3%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc.; - medicines for digestive health (8.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - other (4.2%). Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (41.6%), North America (35.1%), and Asia/Pacific (23.3%).
Employees
24,535
Date Price Change Volume
06/11/26 GBX 338.90 -0.53% 41,825,204
05/11/26 GBX 340.70 +0.92% 76,891,722
04/11/26 GBX 337.60 +3.69% 41,596,752
03/11/26 GBX 325.60 +0.74% 37,215,618
02/11/26 GBX 323.20 +1.19% 68,119,225
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Haleon plc
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.389GBP
Average target price
3.759GBP
Spread / Average Target
+10.91%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Haleon plc